Lifeboat Foundation

NGS — news flash; gene editing corrects genetically linked liver disease.

For the first time, researchers have treated an animal model of a genetic disorder using a viral vector to deliver genome-editing components in which the disease- causing mutation has been corrected. Delivery of the vector to newborn mice improved their survival while treatment of adult animals, unexpectedly, made them worse, according to a new study by investigators from the Perelman School of Medicine at the University of Pennsylvania The team published their findings in Nature Biotechnology.

“Correcting a disease-causing mutation following birth in this animal model brings us one step closer to realizing the potential of personalized medicine,” said senior author James Wilson, MD, PhD, a professor of Medicine and director of the Orphan Disease Center at Penn. “Nevertheless, my 35-year career in gene therapy has taught me how difficult translating mouse studies to successful human treatments can be. From this study, we are now adjusting the gene-editing system in the next phases of our investigation to address the unforeseen complications seen in adult animals.” Wilson is also director of the Penn Gene Therapy Program.

Continue reading “Penn study has implications for developing safe therapies for an array of rare diseases via new gene cut-and-paste methods” »

Genome pioneers “Where Are They Now?”

Fifteen years after publication of the human genome’s first draft sequence, what has become of the hundreds of researchers who worked on the project?

Read more

Aging, inflammation, cancer, and cellular senescence are all intimately interconnected. Deciphering the nature of each thread is a tremendous task, but must be done if preventative and geriatric medicine ever hope to advance. A one dimensional analysis simply will not suffice. Without a strong understanding of the genetic, epigenetic, intercellular, and intracellular factors at work only an incomplete picture can be formed. However, even with an incomplete picture useful therapeutics can and are being developed. One face is cancer, a number of diseases characterized by uncontrolled cell division. The other is slue of degenerative disorders stemming from deterioration in regenerative capacity.

Geroprotectors are a diverse and growing family of compounds that assist in preventing and reversing the unwanted side-effects of aging. Senolytics, a subset of this broad group, accomplish this feat by encouraging the removal of decrepit cells. A few examples include dasatinib, quercetin, and ABT263. Although more research must be done, there are a precious handful of studies accessible to anyone with the inclination to scroll to the works cited section of this article. Those within the life extension community and a few enlightened souls outside of it already know this, but it bears repeating: in the developed world all major diseases are the direct result of the aging process. Accepting this rather simple premise, and you really ought to, should stoke your enthusiasm for the first generation of anti-aging elixirs. Before diving into the details of this promising new pharmaceuticals we must ask what is cellular senescence? What causes it? What purpose does it serve?

Depending on the context in which they are operating a single gene can have positive or negative effects on an organism’s phenotype. Often the gene is exerting both desirable and undesirable influences at the same time. This is called antagonistic pleiotropy. For example, high levels of testosterone can confer several reproductive advantages in youth, but in elderly men can increase their likelihood of developing prostate cancer. Cellular senescence is a protective measure; it is a response to damage that could potentially turn a healthy cell into a malignant one. Understandably, this becomes considerably more complex when one is examining multiple genes and multiple pathways. Identifying all of the players involved is difficult enough. Conboy’s famous parabiosis experiment shows that alterations in the microenviornment, in this case identified and unidentified factors in the blood of young mice, can have be very beneficial to their elders. Conversely, there is a solid body of evidence that shows senescent cells can have a bad influence their neighbors. How can something similar be achieved in humans without having to surgically attach a senior citizen to a college freshman?

Read more

REMINDER: DARPA’s Neural Engineering System Design (NESD) Program Proposers Days is tomorrow and Wed. (February 2–3, 2016) at The Westin Gateway Hotel, 801 N. Glebe Road, Arlington, VA 22203. This is part of the Brain Mind Interface development work. Good thing that the research on Graphene came out recently showing that it is a viable substance for BMIs.

Users of assistive technologies such as screen readers should use the following link to activate Accessibility Mode before continuing: Learn more and Activate accessibility mode.

Read more

Very messed up.

WASHINGTON, Feb. 1 (UPI) — Residents of Appalachia continue to have higher rates of cancer regardless of race and location.

Appalachia is a region of the Eastern United States defined by the presence of the Appalachian Mountains. It stretches from Mississippi to New York and includes 420 counties in 13 states and roughly 25 million people.

Continue reading “Cancer rates still higher in Appalachia, but gap is narrowing” »

YOU GOT A BOT PROBLEM — use DARPA’s BOT Killer”

DARPA shared their method of eliminating “bots.

Bots are a particularly pernicious presence on Twitter. While they can be used for good, (R.I.P., original @horse_ebooks), bots often power spam, scams and, most interestingly, very volatile clusters of political and cultural discussion on Twitter. Last year, DARPA confronted the problem and, according to MIT Tech Review, a new report shows just how researchers were able to identify and shutdown the malicious programs.

Continue reading “Here’s how DARPA trained researchers to kill bots” »

I do believe that there will be a need (especially in certain fields) for humans to BMI technology. I believe over time that this technology will become less and less of an invasive procedure and can even be controlled by the individual to be on or off.

The agency is working on a neural interface that will allow data to be transferred between the brain and digital world.

Read more

The lifting body vehicle will be launched on a United Launch Alliance (ULA) Atlas V rocket and will have the ability to return—along with cargo—by landing at any available airport. SNC’s Dream Chaser is made of non-toxic materials meaning it can touch down on commercial runways and be accessed immediately.

The chance to showcase a reusable spacecraft on government funded missions bodes well for a potential pivot to commercial use. SNC is at the leading edge of private space companies that one day might cater to a more diverse base of consumers like universities, medical companies and individuals.

To learn more about Dream Chaser’s history and development, we spoke to John Roth, Vice President of Business Development for SNC’s Space Systems.

Read more

2 trends that is happening now especially with millennials: car ownership is no longer the desire; and home ownership is out of reach. And, this will impact at a minimum 4 industries — financial, real estate, auto, and insurance industries? Something that many in industry will need to get very creative in addressing to entice the future larger market consumers.

Young people no longer rush to buy their first car, meaning future cities need to think quickly about public transport and the emerging “share economy”, one of Australia’s leading urban futurists says.

Fewer people will “own a car”, “shared” driverless cars will be common and the “Uber” idea of sharing a ride will extend beyond an alternative to taxis, to ‘sharing’ homes, jobs, electric cars, hotel rooms and bikes by 2050.

Continue reading “Young Aussies thinking twice about car ownership: city futurist” »